Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Kanerva

Showing results (91-100 of 124) with videos related to

Pageof 13
Sort By:
Oncotarget|February 26, 2015
Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapyOtto Hemminki, Suvi Parviainen, Juuso Juhila, et al.
Human Gene Therapy|October 14, 2020
Oncolytic Adenovirus Type 3 Coding for CD40L Facilitates Dendritic Cell Therapy of Prostate Cancer in Humanized Mice and Patient SamplesSadia Zafar, Saru Basnet, Inga-Maria Launonen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2013
Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirusAnna Kanerva, Petri Nokisalmi, Iulia Diaconu, et al.
International Journal of Cancer|March 31, 2015
Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humansSimona Bramante, Johanna K Kaufmann, Ville Veckman, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 28, 2015
Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic AdenovirusKristian Taipale, Ilkka Liikanen, Juuso Juhila, et al.
Annals of Medicine|January 26, 2011
In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartmentsSophie Escutenaire, Vincenzo Cerullo, Iulia Diaconu, et al.
Molecular Therapy Oncolytics|April 28, 2016
Overcoming tumor resistance by heterologous adeno-poxvirus combination therapyMarkus Vähä-Koskela, Siri Tähtinen, Susanna Grönberg-Vähä-Koskela, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 3, 2013
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patientsIlkka Liikanen, Laura Ahtiainen, Mari L M Hirvinen, et al.
International Journal of Cancer|December 31, 2013
Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humansSimona Bramante, Anniina Koski, Anja Kipar, et al.
Oncoimmunology|September 14, 2020
Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibitionVictor Cervera-Carrascon, Dafne C A Quixabeira, Joao Manuel Santos, et al.
Pageof 13

Showing results (91-100 of 124) with videos related to

Sort By:
Pageof 13
Oncotarget|February 26, 2015
Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapyOtto Hemminki, Suvi Parviainen, Juuso Juhila, et al.
Human Gene Therapy|October 14, 2020
Oncolytic Adenovirus Type 3 Coding for CD40L Facilitates Dendritic Cell Therapy of Prostate Cancer in Humanized Mice and Patient SamplesSadia Zafar, Saru Basnet, Inga-Maria Launonen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2013
Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirusAnna Kanerva, Petri Nokisalmi, Iulia Diaconu, et al.
International Journal of Cancer|March 31, 2015
Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humansSimona Bramante, Johanna K Kaufmann, Ville Veckman, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 28, 2015
Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic AdenovirusKristian Taipale, Ilkka Liikanen, Juuso Juhila, et al.
Annals of Medicine|January 26, 2011
In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartmentsSophie Escutenaire, Vincenzo Cerullo, Iulia Diaconu, et al.
Molecular Therapy Oncolytics|April 28, 2016
Overcoming tumor resistance by heterologous adeno-poxvirus combination therapyMarkus Vähä-Koskela, Siri Tähtinen, Susanna Grönberg-Vähä-Koskela, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 3, 2013
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patientsIlkka Liikanen, Laura Ahtiainen, Mari L M Hirvinen, et al.
International Journal of Cancer|December 31, 2013
Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humansSimona Bramante, Anniina Koski, Anja Kipar, et al.
Oncoimmunology|September 14, 2020
Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibitionVictor Cervera-Carrascon, Dafne C A Quixabeira, Joao Manuel Santos, et al.
Pageof 13